Osteoporosis Risk Assessment and Management
Answer the following items using your own words. Be objective and concise while being professional.
1. During a case presentation at your clinic, you review four women with predisposing factors for osteoporosis. Which patient is least likely to be at risk for osteoporosis?
A. Nehineza, an overweight African American female with a family history of uterine cancer
B. Cristina, a Hispanic woman living a sedentary life
C. Park-Gim-Ka, an underweight Asian woman with a history of tobacco use
D. Skylar, a Caucasian woman experiencing early onset of menopause.
2. Densitometry results are given as T-scores. Which values would be considered osteopenia?,
3. After prompt analysis of your patient you decide to institute treatment for osteoporosis. ,Which recommendations would you provide to the patient regarding this treatment?
2 PAGES
NO PLAGIARISM MORE THAN 10% PLEASE WILL BE SUBMITTED BY TURNIN IN
3 SCHOLARLY RESOURCES NO OLDER THAN 5 YEARS WITH IN TEXT CITATIONS
APA 7TH EDITION FORMAT
Osteoporosis Risk Assessment and Management
DUE DARTE MARCH 31, 2025The overall prevalence of hypocalcemia and hyperphosphatemia was 57.81% and 89.84%, respectively. Among the ESRD patients, 174 (68.75%) had an iPTH level elevated by more than two times the upper limit of the normal range, and 40 (15.63%) had an iPTH level elevated by more than nine times the upper limit of the normal range.
Hypocalcemia, hyperphosphatemia, elevated iPTH and CRP levels were highly prevalent among ESRD patients. Furthermore, our findings suggest an association between serum ALP levels, iPTH and CRP levels, and leukocyte count.
Baralić et al. (2019) published a study titled “Dual roles of the mineral metabolism disorders biomarkers in prevalent hemodialysis patients: in renal bone disease and in vascular calcification” in the Journal of Medical Biochemistry. Their study likely explored how certain biomarkers associated with mineral metabolism disorders play roles in two common complications in hemodialysis patients: renal bone disease and vascular calcification. APA